Compare · RVMD vs WWB

RVMD vs WWB

Side-by-side comparison of Revolution Medicines Inc. (RVMD) and Windward Bio Group AG (WWB): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both RVMD and WWB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • RVMD is the larger of the two at $34.57B, about 25.6x WWB ($1.35B).
  • RVMD has been more active in the news (15 items in the past 4 weeks vs 14 for WWB).
  • RVMD has more recent analyst coverage (25 ratings vs 0 for WWB).
MetricRVMDWWB
Company
Revolution Medicines Inc.
Windward Bio Group AG
Price
-
-
Market cap
$34.57B
$1.35B
1M return
-18.68%
-
1Y return
+126.61%
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2020
2026
News (4w)
15
14
Recent ratings
25
0
RVMD

Revolution Medicines Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.

WWB

Windward Bio Group AG

Windward Bio Group is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. Our product candidates, WIN378 and WIN027, target clinically validated disease pathways and are engineered to remain in the body for extended periods of time, enabling less frequent dosing than currently available treatments. This design feature is combined with additional properties including enhanced target affinity, dual target binding or effector function silencing. We believe our product candidates have the potential to deliver better clinical outcomes while offering the convenience of less frequent dosing than currently available treatments.

Latest RVMD

Latest WWB